Results 171 to 180 of about 539,217 (308)

The Global Airways in Practice: Long‐term Effects of Mepolizumab With or Without FESS on Type 2 Inflammation in Patients With CRSwNP

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease often associated with asthma. The global airway hypothesis suggests bidirectional inflammatory interactions between upper and lower airways. Mepolizumab, an anti–IL‐5 therapy, treats conditions systemically, while functional endoscopic sinus surgery ...
Jens Tidemandsen, Vibeke Backer, Anne Sophie Homøe, Thomas H. L. Jensen, Kasper Aanæs, Howraman Meteran, Morten Hostrup, Lukas Moesgaard, Christiane Haase, Peter G. Gibson   +9 more
wiley   +1 more source

Integrating a host biomarker with a large language model for diagnosis of lower respiratory tract infection. [PDF]

Nat Commun
Phan HV, Spottiswoode N, Lydon EC, Chu VT, Cuesta A, Kazberouk AD, Richmond NL, Deosthale P, Calfee CS, Langelier CR.   +9 more
europepmc   +1 more source

New approaches to treating chronic obstructive pulmonary disease with Colla corii asini

Animal Models and Experimental Medicine, EarlyView.
Colla corii asini improves chronic obstructive pulmonary disease (COPD) treatment through anti‐inflammatory, antioxidant, immune‐modulatory, and lung‐nourishing effects, addressing current therapeutic challenges via multitarget mechanisms. Abstract Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death and disability ...
Wenchao Zhang, Siman Sun, Xiaoyu Fan, Jiuming He, Qing Li, Hongtao Jin   +5 more
wiley   +1 more source

Chemical Synthesis of Pseudomonas aeruginosa, Staphylococcus aureus, and Acinetobacter baumannii Capsular Polysaccharide Fragments as Leads for Cross‐Protection

Angewandte Chemie, EarlyView.
A total of 16 chemically synthesized capsular polysaccharide (CPS) fragments related to Pseudomonas aeruginosa, Staphylococcus aureus, and Acinetobacter baumannii were analyzed by glycan microarray. Comparative screening revealed three conserved epitopes that act as cross‐protective vaccine lead candidates against multidrug‐resistant (MDR) bacterial ...
Amar Kumar Mishra, Emelie E. Reuber, Diksha Rai, Leif E. Sander, Julia Duerr, Simon Y. Graeber, Marcus A. Mall, Bettina C. Fries, Peter H. Seeberger, Suvarn S. Kulkarni   +9 more
wiley   +2 more sources

Use of Computed Tomography in the Clinical Diagnosis of Lower Respiratory Tract Diseases in Sheep. [PDF]

Vet Sci
Castells E, Quílez P, Lacasta D, Ortín A, Villanueva-Saz S, Climent M, Luján L, Guallar D, Hedman CA, Ruiz H, de Arcaute MR.   +10 more
europepmc   +1 more source

Foreign bodies of the lower respiratory tract

, 2009
A.B. Ugrinovic, V.B. Djukic, Ljiljana Erdevicki, Sava Arsenijevic, Jovica Milovanović, S.D. Andric, N.N. Radoic   +6 more
openalex   +2 more sources

Polydatin alleviates mitochondrial damage and apoptosis of lung epithelial cells by inhibiting toll‐like receptor 4‐dependent macrophage activation in asthma

Animal Models and Experimental Medicine, EarlyView.
The alleviation of asthma by polydatin is dependent on the blockage of the toll‐like receptor 4 (TLR4)/P2X7R synergy in macrophages. The blockage of the TLR4/P2X7R synergy results in decreased release and secretion of interleukin‐1β (IL‐1β) and IL‐18. In epithelial cells, low IL‐1β and IL‐18 levels inhibit mitochondrial damage and apoptosis.
Guangxing Li, Ruobai Liu, Chang Xu, Jianing Yang, Yilan Song, Li Li, Jingzhi Jiang, Liangchang Li, Chongyang Wang, Guanghai Yan   +9 more
wiley   +1 more source

Genetic diversity of <i>Microviridae</i> phages in the human respiratory tract. [PDF]

Front Cell Infect Microbiol
Yang P, Zhang H, Yin L, Chen J, Chen Y, Yang H, Liu Q, Zhang W.   +7 more
europepmc   +1 more source

VITAMIN D SUPPLEMENTATION PROTECT CHILDREN FROM LOWER RESPIRATORY TRACT INFECTION: A CONTROLLED TRIAL

, 2019
Hafiza Hiba Anis Muhammad Arslan Anwar
openalex   +1 more source

Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real‐World Evidence

Annals of Neurology, EarlyView.
Objective The objective of this study was to compare the long‐term safety profiles of ocrelizumab and rituximab in persons with multiple sclerosis (MS). Methods Using retrospective data from the University of California (UC) Health System, we simulated a target clinical trial. The primary cohort from UC San Francisco (UCSF) and a validation cohort from
Gabriel Cerono, Bruce A.C. Cree, Stephen L. Hauser, Sergio E. Baranzini   +3 more
wiley   +1 more source